Stereotactic body radiation therapy as an effective local treatment for advanced hepatocellular carcinoma patients with inferior vena cava and right atrial tumor thrombus

• Published in: BMC gastroenterology Vol. 22; no. 1; pp. 1 - 451
• Main Authors: Zhang, Dan, Li, Qian, Li, Dong, Jia, Jun, Ding, JunQiang, Sun, Jing, Duan, Xuezhang
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 08.11.2022; BioMed Central; BMC
• Subjects: Advanced HCC; Blood clot; Blood clots; Cancer therapies; Care and treatment; Gastroenterology; Hepatitis; Hepatocellular carcinoma; Hepatoma; Immunotherapy; IVCTT; Liver cancer; Liver cirrhosis; Lungs; Medical prognosis; Metastasis; Methods; Palliative care; Patients; Radiation therapy; Radiotherapy; RATT; SBRT; Targeted therapy; Thrombosis; Toxicity; Tumors; Veins & arteries; China
• ISSN: 1471-230X; 1471-230X
• DOI: 10.1186/s12876-022-02556-8

Abstract Background The aim of our study was to evaluate the curative effect and safety of stereotactic body radiation therapy (SBRT) in treating hepatocellular carcinoma (HCC) patients with inferior vena cava (IVCTT) and right atrial tumor thrombus (RATT). Methods This retrospective study included fifteen advanced HCC patients with IVCTT and RATT who were treated with SBRT between 2013 and 2020. The prescribed dose delivered to the tumor was 45–50 Gy/7–10 fx. We report their treatment responses according to survival time and toxicities. Results For these patients, the median follow-up time was 15 months (2–52 months). Local tumor control rates of the treated area were 80% at the time of death or at the last follow-up. The 6-month, 12-month, 18-month and 24-month OS rates were 80.0%, 60.0%, 33.3% and 26.7%, respectively. None of these patients died from the toxicity outcomes and complications of SBRT. Conclusion SBRT is an effective option for advanced HCC patients with IVCTT and RATT.